Swedish Exhibition & Congress Centre

H.I.G. Realty Obtains LEED Platinum Certification in Recently Refurbished Hotel in Switzerland

Retrieved on: 
Tuesday, August 29, 2023
Banking, Urban Planning, Professional Services, Landscape, Interior Design, Architecture, Other Travel, Lodging, Other Construction & Property, Destinations, Vacation, Residential Building & Real Estate, Travel, Commercial Building & Real Estate, Construction & Property, Building Systems, Finance, Asset management, LEED, Art Basel, Certification, Swedish Exhibition & Congress Centre, Gold, ESG, Platinum, Hotel, Basel

"), a leading global alternative investment firm with $58 billion of capital under management, is pleased to announce that it has obtained LEED Platinum certification on the recently refurbished Basel Marriott Hotel in Basel, Switzerland.

Key Points: 
  • "), a leading global alternative investment firm with $58 billion of capital under management, is pleased to announce that it has obtained LEED Platinum certification on the recently refurbished Basel Marriott Hotel in Basel, Switzerland.
  • The property, previously known as Swissôtel Basel, underwent a significant renovation and rebranding programme and is now the Basel Marriott Hotel.
  • As a result of the renovation and rebrand, the hotel is now a leader in its reference market.
  • In addition to achieving LEED Platinum in Basel, we have recently achieved LEED Gold on two of our other assets in Italy.

ITRI and EURECOM Sign an MoU on 6G Cooperation

Retrieved on: 
Tuesday, June 20, 2023
Communication, Partnership, ITRI, Swedish Exhibition Agency, Perception, University, RIS, Research, Industrial Technology Research Institute, Information, Student, Radar, Swedish Exhibition & Congress Centre, European, Exhibition, Memorandum of understanding, Architecture, EURECOM, MOEA, Digital transition, Director general, Creative industries, EU

HSINCHU, June 20, 2023 /PRNewswire/ -- The Industrial Technology Research Institute (ITRI) participated in the 2023 EuCNC & 6G Summit in Gothenburg, Sweden and signed a memorandum of understanding (MoU) on 6G technologies collaboration with leading French research institute EURECOM on June 9.

Key Points: 
  • HSINCHU, June 20, 2023 /PRNewswire/ -- The Industrial Technology Research Institute (ITRI) participated in the 2023 EuCNC & 6G Summit in Gothenburg, Sweden and signed a memorandum of understanding (MoU) on 6G technologies collaboration with leading French research institute EURECOM on June 9.
  • The cooperation is expected to open up opportunities for industries, academia, and research institutions in Taiwan to participate in the EU's 6G project proposals and early-stage verification and testing.
  • The MoU was signed by Dr. Pang-An Ting, ITRI's General Director of the Information and Communications Research Laboratories, and David Gesbert, Director at EURECOM.
  • Under the MoU, both parties will work together on exploring the opportunities in 6G technology through regular exchanges of talents, seminars, and joint research proposals.

Pharming Group convenes the Annual General Meeting of Shareholders 2023

Retrieved on: 
Wednesday, April 5, 2023
Proxy, Corpus, AGM, MBA, Euronext, Swedish Exhibition & Congress Centre, Pharming, Management

LEIDEN, Netherlands, April 5, 2023 /PRNewswire/ -- Pharming Group N.V. ("Pharming" or "the Company") (Euronext: PHARM) (Nasdaq: PHAR) announces that the Company's 2023 Annual General Meeting of Shareholders (AGM) will be held on Wednesday, May 17, 2023, at 14:00 CEST.

Key Points: 
  • LEIDEN, Netherlands, April 5, 2023 /PRNewswire/ -- Pharming Group N.V. ("Pharming" or "the Company") (Euronext: PHARM) (Nasdaq: PHAR) announces that the Company's 2023 Annual General Meeting of Shareholders (AGM) will be held on Wednesday, May 17, 2023, at 14:00 CEST.
  • The Notice to Convene, Explanatory Notes, Voting information, meeting documents and Form of Proxy can be found on the Company's website under Investors/Shareholder Meetings.
  • In addition, the Board of Directors proposes, by way of a binding nomination, to re-appoint Deborah Jorn, MBA, for a period of two years.
  • The AGM will be held at the Corpus Congress Centre, Willem Einthovenstraat 1, 2342 BH in Oegstgeest, the Netherlands.

EIP Pharma Announces Presentation of Neuroimaging Data Exhibiting Potential Effects of Neflamapimod on Cholinergic Structure and Function at AD/PD™ 2023

Retrieved on: 
Monday, April 3, 2023
Nucleus, Neuron, International Conference on Information Systems Security and Privacy, Atrophy, Alzheimer's disease, EOT, Swedish Exhibition & Congress Centre, NBM, Basal forebrain, Biomarker, DGM, MRI, Magnetic resonance imaging, MD, AD, Conference, Structure, MAP, Medical imaging, Neuroscience, Anatomy, Patient

BOSTON, April 3, 2023 /PRNewswire/ -- EIP Pharma Inc., a clinical stage company focused on developing treatments for neurodegenerative diseases, today announced the oral presentation by academic investigators from the Amsterdam University Medical Center of neuroimaging results from a phase 2a clinical study in patients with early Alzheimer's disease (AD) at the International Conference on Alzheimer's and Parkinson's Diseases (AD/PD™) 2023, which took place virtually and in person March 28 – April 1, 2023, in Gothenburg, Sweden.

Key Points: 
  • Structural and MRI assessments had been conducted at baseline and following 12 weeks of treatment with neflamapimod.
  • The potential regression of atrophy and recovery of function in neflamapimod-treated patients in this study suggests a restoration of cholinergic neurons in the NbM and are supportive of data generated in previous preclinical studies that demonstrated neflamapimod reversed the neurodegenerative process in the basal forebrain cholinergic system.
  • "We are encouraged by these findings and are pleased to share these important results with the medical and scientific community."
  • Title: Effects of the p38-Alpha Kinase Inhibitor Neflamapimod on the Basal Forebrain in Patients, Assessed by Structural MRI
    Speaker: Chen-Pei Lin, Department of Anatomy and Neurosciences, Amsterdam University Medical Center
    Location: Gothenburg, Sweden (Swedish Exhibition & Congress Centre; Hall F4+F5)

Progress in New Alzheimer's Therapeutics Based on Biology of Aging Highlighted in Symposium Hosted by Alzheimer's Drug Discovery Foundation (ADDF) at AD/PD™ 2023 International Conference on Alzheimer's and Parkinson's Diseases and Related Neurological Dis

Retrieved on: 
Tuesday, March 21, 2023
Fillit, Reverse-path forwarding, Swedish Exhibition & Congress Centre, LSP, Investment, Drug discovery, Disease, Alzheimer's Drug Discovery Foundation, Ageing, Alzheimer's Research UK, Dementia, Cancer, Cognition, MBA, Research, Brain, Doctor of Philosophy, ARUK, Organization, DSM-IV codes, EQT, International Conference on Emerging Infectious Diseases, Homogeneity and heterogeneity, Wake Forest School of Medicine, Drug development, Gates Ventures, Biology, Entrepreneurship, AD, Building a Future, Therapy, Conference, Pharmaceutical industry, Management, Medical imaging, Alzheimer's disease, MD

NEW YORK, March 21, 2023 /PRNewswire/ -- The Alzheimer's Drug Discovery Foundation will host a symposium, "Building the Future: Novel Approaches and Innovations in Alzheimer's Research" at the AD/PD™ 2023 International Conference on Alzheimer's and Parkinson's Diseases and Related Neurological Disorders, March 28th through April 1st at the Swedish Exhibition & Congress Centre in Gothenburg, Sweden.

Key Points: 
  • This symposium encompasses two sessions.
  • The second session, "Emerging Solutions: Novel Approaches to Treating Alzheimer's Disease," focuses on the biology of aging and promising drugs in the pipeline that target a host of underlying pathologies that contribute to Alzheimer's disease.
  • It features presentations on research, including novel senolytics and repurposing programs, as well as prevention approaches for Alzheimer's and related dementias.
  • These diverse approaches reflect the current Alzheimer's pipeline, where 75% of drugs in clinical trials focus on non-amyloid and tau targets according to a recent report.

Vaxxinity to Present at Upcoming March Scientific and Medical Conferences

Retrieved on: 
Thursday, March 2, 2023
Congress, Cardiology, Conference, Swedish Exhibition & Congress Centre, COVID-19, Toronto Congress Centre, American College, Pharmaceutical industry, Vaccine

CAPE CANAVERAL, Fla., March 02, 2023 (GLOBE NEWSWIRE) -- Vaxxinity, Inc. (Nasdaq: VAXX ), a U.S. company pioneering the development of a new class of immunotherapeutic vaccines, today announced that its scientists and executives will present at three upcoming scientific and medical conferences in March.

Key Points: 
  • CAPE CANAVERAL, Fla., March 02, 2023 (GLOBE NEWSWIRE) -- Vaxxinity, Inc. (Nasdaq: VAXX ), a U.S. company pioneering the development of a new class of immunotherapeutic vaccines, today announced that its scientists and executives will present at three upcoming scientific and medical conferences in March.
  • American College of Cardiology/World Congress of Cardiology 2023 (March 4-6, 2023)
    Vaccine Technology Summit (March 20-21, 2023)
    Title: UB-612, A Cross-Platform COVID-19 Vaccine Booster: Phase 3 Study Results
    AD/PD International Conference (March 28 – April 1, 2023)
    Location: Gothenburg, Sweden (Swedish Exhibition & Congress Centre; Hall F4+F5)
    Title: Preclinical Development of the Novel Tau Vaccine, VXX-301